These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23331711)

  • 21. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
    N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL; Crosby RD; Wang Z
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD; Hurren KM
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
    Tuccinardi D; Farr OM; Upadhyay J; Oussaada SM; Mathew H; Paschou SA; Perakakis N; Koniaris A; Kelesidis T; Mantzoros CS
    Diabetes Obes Metab; 2019 Jun; 21(6):1487-1492. PubMed ID: 30724455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
    Farr OM; Upadhyay J; Gavrieli A; Camp M; Spyrou N; Kaye H; Mathew H; Vamvini M; Koniaris A; Kilim H; Srnka A; Migdal A; Mantzoros CS
    Diabetes; 2016 Oct; 65(10):2943-53. PubMed ID: 27385157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.
    Smith SR; O'Neil PM; Astrup A; Finer N; Sanchez-Kam M; Fraher K; Fain R; Shanahan WR
    Obesity (Silver Spring); 2014 Oct; 22(10):2137-46. PubMed ID: 25044799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP; Kumar RB; Aronne LJ
    Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Hurren KM; Dunham MW
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lorcaserin: a review of its use in chronic weight management.
    Hoy SM
    Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):53-64. PubMed ID: 31770497
    [No Abstract]   [Full Text] [Related]  

  • 34. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial of lorcaserin for weight management.
    Floyd JS; Heckbert SR
    N Engl J Med; 2010 Dec; 363(25):2469; author reply 2469-70. PubMed ID: 21158669
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity.
    Capristo E; Maione A; Lucisano G; Russo MF; Mingrone G; Nicolucci A
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2587-2595. PubMed ID: 34154892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.